Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05785767
Title A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Regeneron Pharmaceuticals
Age Groups: adult | senior
Covered Countries USA | CAN | AUS

Additional content available in CKB BOOST